Please activate JavaScript!
Please install Adobe Flash Player, click here for download

today EAO Paris Sep. 30 & Oct. 1, 2016

business 25th EAO Annual Scientific Meeting 28  For the long term success of den- tal implants the soft tissue attach- ment on the abutment plays an im- portant role. If it is insufficient then plaque accumulation in the pocket can cause gingivitis and subse- quently peri-implantitis when not treated the right way. Unfortunately, the attachment of soft tissue on standard titanium surfaces is very limited as is visible on many histolo- gies where deep pockets down to the abutment-implant-interface are nor- mally visible. In addition, many of the abutment changes in the classi- cal implantology cause trauma which impacts the soft tissue attach- ment even more. At the EAO congress in Paris, the bredent group and DESS the start of a cooperation between the two companies to offer the SKY im- plant user an innovative solution to improve the soft tissue attachment of customised titanium abutments with the Metalive surface. The Metalive process is changing the abutments surface in the sulcus on that way that the connective tissue can attach in a better way. Clinical studies have provided evidence to several registered claims, such as reduced bone resorption, faster healing and bio-adhesion between the titanium surface and connec- tive tissue. To reduce the number of abut- ment changes both companies pro- pose two alternative workflows. In the first workflow, impressions of the SKY implant are taken on the day of implant insertion. Then the customised abutment with Metalive as well as the customised definitive crown made of breCAM. HIPC are designed and manufac- tured. On the day of the exposure of the implant the customized abut- ment and crown are placed and the treatment is finished. In the second workflow, impres- sions are also taken and the custom- ised abutment with Metalive (a lab- oratory abutment copy functioning as base to produce aesthetic ceramic crowns is produced at the same time) as well as the customised de- finitive crown made of breCAM. HIPC are designed and manufac- tured. On the day of the exposure of the implant the customized abut- ment with Metalive surface is in- serted and restored with the tempo- rary crown. In the dental lab on the customised abutment copy the de- finitive crown is produced. After the soft tissue healing the temporary crown is exchanged with the defini- tive crown. With the customised abutment with Metalive and the reduced workflows, both companies expect better clinical results with much lower costs compared to traditional implantology. This way, they believe that more patients will undergo im- plant treatment instead of a getting a conventional bridge with all its dis- advantages.  Bredent, Germany www.bredent.com Booth S11 BREDENT GROUP AND DESS COOPERATE FOR IMPROVED SOFT TISSUE ATTACHMENT  Over 10 million dental implants are placed every year around the world and it is a well-known fact that they need good care to last for a long time. Proper oral hy- giene reduces the risk for peri-im- plant mucositis and peri-implanti- tis, common diseases among im- plant patients, says Anna Nilvéus Olofsson, Manager Odontology and Scientific Affairs at TePe. That is why the company is offering the uniquely angled TePe Implant Care for keeping the lingual and palatal implant surfaces free from plaque. The Swedish oral hygiene com- pany currently offers a wide range of cleaning devices for different types of implants. The well-known TePe Interdental Brush, for exam- ple, is an excellent tool for inter-im- plant cleaning. However, the range also includes a whole assortment of products to clean all surfaces of the implant. TePe has been developing high-quality oral hygiene prod- ucts, including interdental brushes, dental sticks, floss and toothbrushes, in collaboration with dental experts since 1965. Based in Malmö in southern Swe- den, the company currently ex- ports interdental brushes, tooth- brushes and dental sticks from its subsidiaries in France, Germany, Italy, the Netherlands, Sweden and the UK to 60 countries worldwide. Last year, the company achieved a turnover of SEK 600 million (€ 62.8 million).  TePe, Sweden www.tepe.com Booth S20 TAILORED DENTAL IMPLANT CARE WITH TEPE PRODUCTS  Since dental implants have be- come a mainstream treatment op- tion, clinicians face ever-increasing patient expectations. Nowadays, pa- tients expect successful treatment results irrespective of their bone quality, age, lifestyle, or medical his- tory. For over six decades, Straumann has made significant contributions to the progressing field of dental im- plants. Through pioneering innova- tion, the company has redefined the bounda- ries of clinical possi- bilities for both dental professionals and pa- tients. Ten years ago, Straumann pioneered accelerated osseointegration with Straumann SLActive, reducing the healing pe- riod down to 3–4 weeks in all indica- tions.1 This innovation made faster treatment, shorter healing time, and better outcomes a reality. Achieving predictable treatment outcomes has been the main focus of the SLActive clinical development strategy ever since. Together with leading clinicians worldwide, Strau- mann has studied the clinical perfor- mance of SLActive implants under the most challenging medical condi- tions and treatment protocols to demonstrate the outstanding healing capacity of the SLActive surface. As new insights emerge and new data becomes available,2,3 clinicians can discover how they can benefit from the truly phenomenal perfor- mance of SLActive to maximise their patients’ healing capabilities. At- tendees of this year’s annual scien- tific congress of The EAO are invited to discover the brand NEW SLActive data that shows incredible perfor- mance in the most challenging con- ditions.  Straumann, Switzerland slactive.straumann.com Booth D4 1 Straumann SLActive implants compared to Strau- mann SLA implants. Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early os- seointegration to hy¬drophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011 Apr;22(4):349-56. doi: 10.1111/j.1600- 0501.2011.02172.x. 2 Nicolau P, Guerra F, Reis R, Krafft T, Benz K , Jack- owski J 10-year results from a randomized controlled multicenter study with immediately and early load- ed SLActive implants in posterior jaws. Accepted for oral presentation at 25th Annual Scientific Meeting of the European Association of Osseointegration – 29 Sep – 1 Oct 2016, Paris. 3 Patients treated with dental implants after surgery and radio-chemotherapy of oral cancer. Heberer S, Kilic S, Hossamo J, Raguse J-D, Nelson K. Rehabili- tation of irradiated patients with modified and con- ventional sandblasted, acid-etched implants: prelim- i¬nary results of a split-mouth study. Clin. Oral Impl. Res. 22, 2011; 546–551. STRAUMANN TO OFFER NEW INSIGHTS INTO SLACTIVE For over six decades, Straumann® has made significant con- tributions to progress in the field of dental implants. Through pioneering innovation, we have redefined the boundaries of possibility for dental professionals and patients. 10 years ago, with Straumann® SLActive®, we pioneered accelerated osse- ointegration, reducing the healing period down to 3–4 weeks in all indications.¹ This innovation made faster treatment, shorter healing time, and better outcomes a reality. As dental implants are now becoming a mainstream treat- ment option, clinicians face ever-increasing patient expecta- tions. Nowadays patients expect successful treatment results irrespective of their bone quality, age, lifestyle, or medical history. Achieving predictable treatment outcomes has been the main focus of the SLActive® clinical development strategy. Togeth- er with leading clinicians worldwide, Straumann has studied the clinical performance of SLActive® Implants under the most challenging medical conditions and treatment proto- cols to demonstrate the outstanding healing capacity of the SLActive® surface. As new insights emerge and new data becomes available, discover how you can benefit from the truly phenomenal performance of SLActive® to maximize your patients’ healing capabilities: Discover the brand NEW SLActive® data that shows incredi- ble performance in the most challenging conditions. Visit the Straumann booth D4 or read more on: http://slactive.straumann.com. 1 Straumann SLActive implants compared to Straumann SLA implants. Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early osseointegration to hy- drophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011 Apr;22(4):349-56. doi: 10.1111/j.1600-0501.2011.02172.x. 2 Nicolau P, Guerra F, Reis R, Krafft T, Benz K , Jackowski J 10-year results from a random- izedcontrolledmulticenterstudywithimmediatelyandearlyloadedSLActiveimplants in posterior jaws. Accepted for oral presentation at 25th Annual Scientific Meeting of the European Association of Osseointegration – 29 Sep – 1 Oct 2016, Paris. 3 Patients treated with dental implants after surgery and radio-chemotherapy of oral cancer. Heberer S, Kilic S, Hossamo J, Raguse J-D, Nelson K. Rehabilitation of irradiated patients with modified and conventional sandblasted, acid-etched implants: prelimi- nary results of a split-mouth study. Clin. Oral Impl. Res. 22, 2011; 546–551. Straumann® SLActive® Performance beyond imagination. 98.2% survival rate IMPLANT SURVIVAL RATE IN IMMEDIATE LOADING AFTER 10 YEARS² Randomised controlled multicenter study Randomised clinical trial IMPLANT SUCCESS RATE IN IRRADIATED PATIENTS WITH COMPROMISED BONE3 100% success rate Ad_SLActive_Alex.indd 1 13.09.16 17:45 For over six decades, Straumann® has made significant con- tributions to progress in the field of dental implants. Through pioneering innovation, we have redefined the boundaries of possibility for dental professionals and patients. 10 years ago, with Straumann® SLActive®, we pioneered accelerated osse- ointegration, reducing the healing period down to 3–4 weeks in all indications.¹ This innovation made faster treatment, shorter healing time, and better outcomes a reality. As dental implants are now becoming a mainstream treat- ment option, clinicians face ever-increasing patient expecta- tions. Nowadays patients expect successful treatment results irrespective of their bone quality, age, lifestyle, or medical history. Achieving predictable treatment outcomes has been the main focus of the SLActive® clinical development strategy. Togeth- er with leading clinicians worldwide, Straumann has studied the clinical performance of SLActive® Implants under the most challenging medical conditions and treatment proto- cols to demonstrate the outstanding healing capacity of the SLActive® surface. As new insights emerge and new data becomes available, discover how you can benefit from the truly phenomenal performance of SLActive® to maximize your patients’ healing capabilities: Discover the brand NEW SLActive® data that shows incredi- ble performance in the most challenging conditions. Visit the Straumann booth D4 or read more on: http://slactive.straumann.com. 1 Straumann SLActive implants compared to Straumann SLA implants. Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early osseointegration to hy- drophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011 Apr;22(4):349-56. doi: 10.1111/j.1600-0501.2011.02172.x. 2 Nicolau P, Guerra F, Reis R, Krafft T, Benz K , Jackowski J 10-year results from a random- izedcontrolledmulticenterstudywithimmediatelyandearlyloadedSLActiveimplants in posterior jaws. Accepted for oral presentation at 25th Annual Scientific Meeting of the European Association of Osseointegration – 29 Sep – 1 Oct 2016, Paris. 3 Patients treated with dental implants after surgery and radio-chemotherapy of oral cancer. Heberer S, Kilic S, Hossamo J, Raguse J-D, Nelson K. Rehabilitation of irradiated patients with modified and conventional sandblasted, acid-etched implants: prelimi- nary results of a split-mouth study. Clin. Oral Impl. Res. 22, 2011; 546–551. Straumann® SLActive® Performance beyond imagination. 98.2% survival rate IMPLANT SURVIVAL RATE IN IMMEDIATE LOADING AFTER 10 YEARS² Randomised controlled multicenter study Randomised clinical trial IMPLANT SUCCESS RATE IN IRRADIATED PATIENTS WITH COMPROMISED BONE3 100% success rate Ad_SLActive_Alex.indd 1 13.09.16 17:45 Ad_SLActive_Alex.indd 113.09.1617:45 Ad_SLActive_Alex.indd 113.09.1617:45

Seitenübersicht